84 related articles for article (PubMed ID: 12645297)
1. [The concept of nephroprotection: toward preventive and curative therapies for renal sclerosis].
Ronco P
J Soc Biol; 2002; 196(4):285-91. PubMed ID: 12645297
[TBL] [Abstract][Full Text] [Related]
2. [Vasoactive peptides and the development of renal sclerosis: contribution of transgenes].
Dussaule JC; Boffa JJ; Tharaux PL; Flamant M; Fakhouri F; Chatziantoniou C
J Soc Biol; 2002; 196(4):275-80. PubMed ID: 12645295
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
4. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
6. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
7. Role of anti-TGF-beta antibodies in the treatment of renal injury.
Gagliardini E; Benigni A
Cytokine Growth Factor Rev; 2006; 17(1-2):89-96. PubMed ID: 16257566
[TBL] [Abstract][Full Text] [Related]
8. Methods of cardio-renal protection in non-diabetic chronic nephropathies.
Ruggenenti P; Remuzzi G
Rocz Akad Med Bialymst; 2004; 49():116-23. PubMed ID: 15631326
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta and Smad signalling in kidney diseases.
Wang W; Koka V; Lan HY
Nephrology (Carlton); 2005 Feb; 10(1):48-56. PubMed ID: 15705182
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
[TBL] [Abstract][Full Text] [Related]
11. Altered regulation of renin-angiotensin, endothelin and natriuretic peptide systems in rat kidney with chronic unilateral ureteral obstruction.
Bae EH; Kim IJ; Park JW; Ma SK; Choi KC; Lee JU; Kim SW
Urol Int; 2007; 79(2):170-6. PubMed ID: 17851289
[TBL] [Abstract][Full Text] [Related]
12. Reversal of renal disease: is it enough to inhibit the action of angiotensin II?
Dussaule JC; Chatziantoniou C
Cell Death Differ; 2007 Jul; 14(7):1343-9. PubMed ID: 17396129
[TBL] [Abstract][Full Text] [Related]
13. High glucose induces macrophage inflammatory protein-3 alpha in renal proximal tubule cells via a transforming growth factor-beta 1 dependent mechanism.
Qi W; Chen X; Zhang Y; Holian J; Mreich E; Gilbert RE; Kelly DJ; Pollock CA
Nephrol Dial Transplant; 2007 Nov; 22(11):3147-53. PubMed ID: 17664181
[TBL] [Abstract][Full Text] [Related]
14. The renal tubule in the progression of chronic renal failure.
Palmer BF
J Investig Med; 1997 Aug; 45(6):346-61. PubMed ID: 9291690
[No Abstract] [Full Text] [Related]
15. Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system.
Inserra F; Basso N; Ferder M; Userpater M; Stella I; Paglia N; Inserra P; Tenembaum D; Ferder L
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):341-6. PubMed ID: 19574289
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
Cantarovich F; Rangoonwala B
Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
[TBL] [Abstract][Full Text] [Related]
17. CD36 is a novel and potential anti-fibrogenic target in albumin-induced renal proximal tubule fibrosis.
Yang YL; Lin SH; Chuang LY; Guh JY; Liao TN; Lee TC; Chang WT; Chang FR; Hung MY; Chiang TA; Hung CY
J Cell Biochem; 2007 Jun; 101(3):735-44. PubMed ID: 17226761
[TBL] [Abstract][Full Text] [Related]
18. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
Negri AL
J Nephrol; 2004; 17(4):496-503. PubMed ID: 15372410
[TBL] [Abstract][Full Text] [Related]
19. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis.
Ruíz-Ortega M; Gómez-Garre D; Alcázar R; Palacios I; Bustos C; González S; Plaza JJ; González E; Egido J
J Hypertens Suppl; 1994 Jul; 12(4):S51-8. PubMed ID: 7965275
[TBL] [Abstract][Full Text] [Related]
20. Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Renaud IM; Chainey A; Belair MF; Mandet C; Michel O; Myara I; Chevalier J; Plante GE
Fundam Clin Pharmacol; 2004 Aug; 18(4):437-47. PubMed ID: 15312150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
